Navigation Links
Can cancer drugs combine forces?
Date:8/16/2007

Individuals with chronic myeloid leukemia (CML) are treated first with a drug known as imatinib (Gleevec), which targets the protein known to cause the cancer (BCR-ABL). If their disease returns, because BCR-ABL mutants emerge that are resistant to the effects of imatinib, individuals are treated with a drug known as dasatinib (SPRYCEL), which targets BCR-ABL in a different way. However, patients that relapse after treatment with dasatinib, because BCR-ABL mutants emerge that are resistant to the effects of this drug, are now beginning to be seen in the clinic. Researchers from Memorial Sloan-Kettering Cancer Center, New York, now suggest that treating patients with a combination of the drugs might decrease the chance of the cancer returning, or at the very least increase the time before a relapse occurs

In the study, which appears online on August 16 in advance of publication in the September print issue of the Journal of Clinical Investigation, Charles Sawyers and colleagues show that 2 of 12 patients whose cancer had returned after treatment with dasatinib responded to retreatment with imatinib. Analysis of the BCR-ABL proteins from these patients revealed that their BCR-ABL had only the dasatinib-resistance mutation. By contrast, the BCR-ABL proteins of the other patients had either a single mutation that rendered the protein resistant to both dasatinib and imatinib or had two mutations, one rendering the protein resistant to imatinib and one rendering the protein resistant to dasatinib. A third drug that can target dasatinib- and imatinib-resitant BCR-ABL is currently in clinical trials. The authors therefore suggest that rather than treating CML patients with the drugs that target BCR-ABL sequentially, they should receive all the drugs when they are first diagnosed with the disease so that the emergence of the drug-resistant forms of BCR-ABL might be prevented, or at least delayed.


'/>"/>
Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Vitamin B12 can help in detecting cancers
6. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
7. Consensus on "Combination Therapy" for Breast Cancer
8. Cancers of Colon & Rectum linked to Cigarette Smoking
9. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
10. The Cancer Rumour mill working over time
11. Want skin cancer? Please have a cigarette
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of ... Change and Your Health on Voice of America, declared on her radio program in ... to the fact that when these bullies attack leaders in corporate America, they are ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 Media’s Live From ... Folio: Marketing Awards competition. Live From won in the Use of Social Media ... ultimately successful projects undertaken by the media industry’s most innovative marketing professionals. ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, LA.c., a certified ... Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with fertility ... patients realize their family building goals. Acupuncture helps fertility patients by ...
(Date:12/7/2016)... , ... (PRWEB) December 07, 2016 , ... ... nonprofit for individuals impacted by cerebral cavernous angiomas, was awarded a grant from ... a patient engagement program. New Mexico has more people with cavernous angioma than ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... their brain networks that can be seen on a type of MRI, according ... is a progressive disorder of the central nervous system characterized by tremors or ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Dec. 7, 2016  The Corporate Whistleblower Center ... to call them anytime at 866-714-6466 if they possess ... sell more drugs. Aside from the innocent patients frequently ... well, because often-times these practices target Medicare recipients or the ... ...
(Date:12/7/2016)... SCIENCE PARK , Israel , ... (TASE: KDST) announced today the signing of a memorandum of understanding ... companies. The synergy between the companies will assist in expediting Kadimastem,s ... worldwide leader in innovative treatment for severe diseases in general and ... , ...
(Date:12/7/2016)... Dec. 7, 2016  Organovo Holdings, Inc. (NASDAQ: ... company focused on delivering scientific and medical breakthroughs ... Chairman and Chief Executive Officer Keith Murphy ... Wednesday, December 14, 2016 at 1:00 p.m. Eastern ... not yet familiar with the Company, an informational ...
Breaking Medicine Technology: